Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers

NCT02198287 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2014-07-23

No results posted yet for this study

Summary

Safety, tolerability and pharmacokinetic study of BIIX 1 XX in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

BIIX 1 XX inhalation solution

single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-01-31
Primary Completion
1999-04-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02198287 on ClinicalTrials.gov